Progression of joint damage in early rheumatoid arthritis: Association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies

Arthritis and Rheumatism

Volumn 58, Issue 5, 2008, Pages 1293-1298

  De Vries Bouwstra, J K ^a,b   Goekoop Ruiterman, Y P M ^b   Verpoort, K N ^b   Schreuder, G M T ^b   Ewals, J A P M ^c   Terwiel, J P ^d   Ronday, H K ^c   Kerstens, P J S M ^e   Toes, R E M ^b   De Vries, R R P ^b   Breedveld, F C ^b   Dijkmans, B A C ^a   Huizinga, T W J ^b   Allaart, C F ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HAGA HOSPITAL   (Netherlands)

^d Infection and Immunology   (Netherlands)

^e JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA DR ANTIGEN; INFLIXIMAB; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTHROPATHY; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM; SHARP VAN DER HEIJDE SCORE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DISEASE PROGRESSION; FEMALE; HLA-DR ANTIGENS; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; RHEUMATOID FACTOR; SULFASALAZINE;

EID: 43949096193     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23439     Document Type: Article

References (17)

1. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006;65:453-8.
2. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13.
3. Vos K, van der Horst-Bruinsma IE, Hazes JM, Breedveld FC, le Cessie S, Schreuder GM, et al. Evidence for a protective role of the human leukocyte antigen class II region in early rheumatoid arthritis. Rheumatology (Oxford) 2001;40:133-9.
4. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
5. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
6. Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001;44:1736-43.
7. Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003;62:611-6.
8. Lard LR, Visser H, Speyer I, van der Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
9. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis Rheum 2005;52:3381-90.
10. Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406-15.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LM, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
13. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
14. Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744-9.
15. Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8.
16. Van den Berg WB, van Riel PL. Uncoupling of inflammation and destruction in rheumatoid arthritis: myth or reality? [editorial]. Arthritis Rheum 2005;52:995-9.
17. Morand EF. Effects of glucocorticoids on inflammation and arthritis. Curr Opin Rheumatol 2007;19:302-7.